echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The market potential of drug use for under-eye disease is to be excavated

    The market potential of drug use for under-eye disease is to be excavated

    • Last Update: 2021-02-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    With the development of medical and health services in China, although many diseases have been controlled, the incidence of age-related diseases and metabolic-related diseases has increased rapidly, especially ophthalmological diseases. On World Vision Day just past, Xu Xun, a well-known Chinese ophthalmologist and executive director of the Shanghai Eye Disease Prevention and Control Center, told the Medical Economics Daily that the trend is very obvious and unique in China.
    it is understood that the World Health Organization identified three general blind eye diseases are cataracts, glauclear eyes and macular degeneration. Xu Xun introduced, with the WHO called for the three rough blind eye diseases, China's blind eye disease spectrum in addition to glauco and cataracts, macular degeneration as the representative of many eye diseases are still silent killers. Industry analysis, the current use of drugs for eye disease is still small, the market development potential is huge, to be dug deep.has great potential for the domestic market
    According to data from the CFDA Southern Institute of Pharmaceutical Economics, the number of patients with vascular disease at the bottom of the eye in China is as high as 11.6 million. Experts say that standing at the inflection point of an aging population, the high incidence of under-eye disease requires the continuous development of innovative drugs. Internationally, under-eye neovascular drugs have produced several new drugs, including Lucentis, developed in collaboration with Roche and Novarma, Eylea, developed by Regeneron in collaboration with Bayer, Avastin for Roche's cancer treatment, and Compaqsip, developed by China.
    first listed in the U.S. in 2006, with global sales of $4,039 million in 2015 and Eylea in 2011 and $4,050 million in 2015. Avastin and Lucentis have now entered the Chinese market, with the former entering the Chinese market in 2010, the latter approved in 2012, and compassip, a monoclonal antibody developed by Chengdu Kanghong Pharmaceuticals for under-eye vascular disease, officially launched in April 2014 with sales of RMB267 million in 2015.
    from the Mienet market report statistics, the current proportion of ophthalmology drugs in the country, still mainly anti-fatigue products (36%), followed by anti-inflammatory (30%). Cataract drug use is growing rapidly (16.94%), while glaucosis, under-eye disease, dry eye disease, the proportion of these foreign larger drug use areas is still very low, but also foreshadows the potential space of the domestic market.
    , experts also pointed out that the high degree of complexity of new vascular diseases under the eye, the large number of sick people, low public awareness, has become China's ophthalmology and health care industry is facing three major problems.The need for strict control of new drugs
    In fact, the scale of domestic ophthalmology drugs is still very small, the structure of the therapeutic field and the international also have significant differences, both in terms of investment and enterprise research and development direction provides opportunities. Enterprises can also make achievements in ophthalmology, mature products to carry out reasonable adaptive development, to tap greater potential.
    However, Professor Zhao Jialiang of Beijing Concord Hospital also told reporters: "It should be noted that the current development of ophthalmology in China is still relatively fast, the reason is that China's ophthalmologists and ophthalmologists, they support the development of China's ophthalmology industry; Research and development, production and sales of enterprises, their efforts to make clinicians more exposed to new things, improve the level of Chinese ophthalmologists; Zhao
    also stressed that new drugs benefit patients and require strict control by clinicians. It is reported that between 2000 and 2012, Zhao Jialiang led and participated in the completion of a number of photodynamic therapy and anti-angiogenic drug Leizhu monoantigen clinical trials, "before the use of photodynamic therapy, age-related macular degeneration patients are completely available, can only watch a little loss of vision." And the birth of drugs such as leizhu monoantigen, so that the number of injections reduced, long-term maintenance, so that a considerable number of people can save vision.
    Zhao Jialiang further said that in the modern sense of eye health should have three meanings: first, people with eye diseases can get timely treatment, so that their eyes no longer blind; From the past prevention and treatment of blindness, to now pay attention to the general eye health, eye health has become an important part of the construction of 'healthy China'. With government-led, innovative research and development, and the efforts of all sectors of society, we are confident that we can overcome new eye diseases. Zhao Jialiang said. (Medical Economics)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.